Vistagen Provides Corporate Update and Reports Fiscal 2023 Third Quarter Financial Results

Pherin acquisition completed; all future royalty payment obligations related to PH94B and PH10 eliminated, three new drug candidates added to Vistagen’s pipelinePH94B Phase 3 program for social anxiety disorder advancing towards important next stepsPH10 Phase 1 study initiated to facilitate plans for Phase 2B develo...

Related Keywords

Mexico ,United States ,Shawn Singh ,Nate Hitchings ,Mark Flather ,Company Phase ,Pherin Pharmaceuticals ,Drug Administration ,Exchange Commission ,International Number Toll ,Acquisition Of Pherin Pharmaceuticals Inc ,Pherin Pharmaceuticals Inc ,Chief Executive Officer ,Liebowitz Social Anxiety Scale ,New Drug ,Label Study ,Fast Track ,Probenecid Phase ,Quarter Financial ,Dial In Number ,Annual Report ,Quarterly Report ,Seriesb Preferred ,Investor Relations ,